Search
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis. … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient.
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalTherapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999]. … Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia
Tick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigational[A237520] Originally developed by Baxter International Inc., TICOVAC was subsequently acquired by Pfizer Inc. in 2014.[L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050] … Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable.
Alfuzosin
go.drugbank.com/drugs/DB00346Approved[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.
Synonyms: (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamideProducts: ALFUZOSIN RATIO UNO 10MGAlosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnAlosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured … Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes.
Streptomycin
go.drugbank.com/drugs/DB01082ApprovedInvestigationalVet approved[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as … Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.
Synonyms: 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranosideRemifentanil
go.drugbank.com/drugs/DB00899ApprovedInvestigationalRemifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: REMIFENTANILO 2MG POLVO PARA RECONSTITUIR A SOLUCION INYECTABLE O INFUSION INTRAVENOSA, REMIFENTANILO 5MG POLVO POLVO LIOFILIZADO PARA SOLUCIÓN INYECTABLE O INFUSIÓN INTRAVENOSA.Inactive phospholipase C-like protein 1
go.drugbank.com/bio_entities/BE0001081TargetHumansShows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A receptor (By similarity).
Synonyms: Phospholipase C-related but catalytically inactive proteinBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019] … Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils